Overview

Ketamine for Suicidality in Bipolar Depression

Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to compare the effectiveness of two medications, Ketamine and Midazolam, for rapidly relieving suicidal thoughts in people suffering from bipolar depression. The first drug, ketamine, is an experimental antidepressant that early studies have shown may quickly reduce suicidal thoughts, but we are not sure how well it may work. Midazolam, the comparison drug, is not thought to reduce depression or suicidal thoughts.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborator:
Brain & Behavior Research Foundation
Treatments:
Ketamine
Midazolam